Key facts
- Ascendia Pharmaceuticals’s last known valuation is $14.0M (Oct 2024).
- It has raised $17.5M across 4 recorded rounds; the latest was Seed Round ($2.5M) in May 2025.
- Notable investors include Signet Healthcare Partners.
- Ascendia Pharmaceuticals has filed 4 Form Ds with the SEC since 2021, most recently Jun 2025 ($2.5M sold to 9 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Ascendia Pharmaceuticals
Funding rounds
4 roundsAbout Ascendia Pharmaceuticals
Operator of a contract-development-and-manufacturing (CDMO) company dedicated to the development of enhanced formulations for pre-clinical and clinical-stage drug candidates and marketed drug products. The company offers a comprehensive suite of pre-formulation, formulation development, manufacturing, and stability services for parental, oral, and topical dosage forms as well as analytical method development and validation services for those dosage forms, thereby providing clients with specialty pharmaceutical products and novel formulation technologies that help overcome challenging drug delivery problems.
- Sector
- Business Products and Services (B2B)
- HQ
- North Brunswick, NJ, United States
- Founded
- 2012
- Employees
- 100
- Website
- ascendiacdmo.com/
- Ownership
- Privately Held (backing)
Ascendia Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ascendia Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ascendia Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.